SCHEMBL526044

SCHEMBL526044

CC(C)(O)c1ccc(OC(=O)c2ccccc2O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.65
HSD17B10 Q99714 3/20 0.65
ALOX15 P16050 2/20 0.65
MAPT P10636 7/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TDP1 Q9NUW8 4/20 0.50
LMNA P02545 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TSHR P16473 1/20 0.50
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
CYP3A4 P08684 2/20 0.44
ADORA3 P0DMS8 2/20 0.44
CHRM1 P11229 2/20 0.44
TBXA2R P21731 2/20 0.44
SLC6A2 P23975 2/20 0.44
ADRA1A P35348 2/20 0.44
TP53 P04637 1/20 0.44
PDE4A P27815 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29645273 0.89 MAPT (0.68) HPGDHSD17B10ALOX15MAPTNPSR1
SCHEMBL3830500 0.89 HPGD (0.67) HPGDHSD17B10ALOX15MAPTNPSR1
SCHEMBL77201 0.89 MAPT (0.68) HPGDHSD17B10ALOX15MAPTNPSR1
SCHEMBL28320193 0.88 MAPT (0.67) HPGDHSD17B10ALOX15MAPTNPSR1
Phenyl Salicylate SCHEMBL6429855 0.86 HSD17B10 (0.73) HPGDHSD17B10ALOX15MAPTNPSR1
SCHEMBL7614991 0.85 HPGD (0.88) HPGDHSD17B10ALOX15MAPTNPSR1
SCHEMBL8205574 0.84 TDP1 (0.67) HPGDHSD17B10ALOX15MAPTNPSR1
Phenol SCHEMBL28229407 0.84 HSD17B10 (0.64) HPGDHSD17B10ALOX15MAPTNPSR1
SCHEMBL698506 0.82 HPGD (0.58) HPGDHSD17B10ALOX15MAPTNPSR1
SCHEMBL9431524 0.82 MAPT (0.60) HPGDHSD17B10ALOX15MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168227-B2 Modified powder and cosmetic composition using the same SHISEIDO CO., LTD. (JP) 2012-05-01 US claimed
US-20100047185-A1 ACTVIE SUBSTANCE COMBINATION ISDIN S.A. (ES) 2010-02-25 US claimed
WO-2008083975-A1 LIGHT-STABILIZED COMPOSITION ISDIN S.A. (ES) 2008-07-17 WO claimed
WO-2008083974-A1 ACTIVE SUBSTANCE COMBINATION ISDIN S.A. (ES) 2008-07-17 WO claimed
WO-2008067928-A1 UV ABSORBING COMPOSITIONS CONTAINING A PYRROLYLTRIAZINE ISDIN S.A. (ES) 2008-06-12 WO claimed
US-20070253989-A1 Modified Powder and Cosmetic Composition Using the Same SHISEIDO CO., LTD. (JP) 2007-11-01 US claimed
EP-4372042-A2 RESIN ADDITIVE COMPOSITION, THERMOPLASTIC RESIN COMPOSITION, AND MOLDED ARTICLE THEREOF Adeka Corporation (JP) 2024-05-22 EP disclosed
EP-4358933-A1 COPOLYMER THICKENING COMPOSITION COMPRISING AT LEAST ONE OIL AND AT LEAST ONE POLY(ITACONATE) FOR THICKENING POLAR OR APOLAR OILS Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2024-05-01 EP disclosed
EP-4358932-A1 THICKENING COMPOSITION FOR THICKENING POLAR OR NON-POLAR OILS Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2024-05-01 EP disclosed
EP-4349418-A2 TOPICALLY ADMINISTRABLE HELICHRYSUM STOECHAS PLANT DEDIFFERENTIATED CELL LYSATE (LY) FOR REMOVING OR REDUCING SKIN INFLAMMATION Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2024-04-10 EP disclosed
EP-4106784-B1 TOPICALLY ADMINISTRABLE LYSATE (LY) OF DEDIFFERENTIATED CELLS OF THE PLANT HELICHRYSUM STOECHAS FOR ELIMINATING OR REDUCING INFLAMMATION OF THE SKIN SOC DEXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2024-04-03 EP disclosed
US-20240099955-A1 SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF HTL BIOTECHNOLOGY INNOVATION INC. 2024-03-28 US disclosed
EP-4331686-A2 TEMPERATURE-STABLE ALKANE AND ESTER COMPOSITIONS, THEIR USE AS EMOLLIENT AGENTS, AND EMULSIONS COMPRISING THEM Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2024-03-06 EP disclosed
EP-0697212-A2 Deodorant cosmetic composition superior in resistance to discoloration and dispersion SHINAGAWA FUEL CO., LTD. (JP) 1996-02-21 EP disclosed
EP-0487404-B1 External dermatological composition HAYASHIBARA BIOCHEM LAB (JP) 1995-10-11 EP disclosed
US-5427771-A Stable dispersion in cosmetically acceptable vehicle with adjuvants L'OREAL (FR) 1995-06-27 US disclosed
WO-1995009895-A1 ULTRAVIOLET SHIELDING COMPOSITE FINE PARTICLES, METHOD FOR PRODUCING THE SAME, AND COSMETICS KAO CORPORATION (JP) 1995-04-13 WO disclosed
EP-0487404-A1 External dermatological composition KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 1992-05-27 EP disclosed
US-5000937-A Transparent cosmetic composition that reflects infrared radiation and its use for protecting the human epidermis against infrared radiation L'OREAL (FR) 1991-03-19 US disclosed
EP-0211183-A2 Use of ubidecarenone(ubiquinone-10) as an antichromatotic agent Eisai Co., Ltd. (JP) 1987-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047185-A1 ACTVIE SUBSTANCE COMBINATION UGT2B17, TACR2, UGT1A1 HPGD 601/4885HSD17B10 396/4885ALOX15 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.